Myriad Genetics (MYGN) Operating Leases: 2019-2025
Historic Operating Leases for Myriad Genetics (MYGN) over the last 6 years, with Sep 2025 value amounting to $84.9 million.
- Myriad Genetics' Operating Leases fell 6.29% to $84.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.9 million, marking a year-over-year decrease of 6.29%. This contributed to the annual value of $87.9 million for FY2024, which is 9.75% down from last year.
- According to the latest figures from Q3 2025, Myriad Genetics' Operating Leases is $84.9 million, which was down 1.51% from $86.2 million recorded in Q2 2025.
- In the past 5 years, Myriad Genetics' Operating Leases ranged from a high of $130.9 million in Q4 2022 and a low of $5.9 million during Q1 2023.
- In the last 3 years, Myriad Genetics' Operating Leases had a median value of $87.4 million in 2025 and averaged $67.1 million.
- Its Operating Leases has fluctuated over the past 5 years, first plummeted by 95.21% in 2023, then soared by 1,498.31% in 2024.
- Quarterly analysis of 5 years shows Myriad Genetics' Operating Leases stood at $79.3 million in 2021, then spiked by 65.07% to $130.9 million in 2022, then fell by 25.59% to $97.4 million in 2023, then decreased by 9.75% to $87.9 million in 2024, then fell by 6.29% to $84.9 million in 2025.
- Its Operating Leases stands at $84.9 million for Q3 2025, versus $86.2 million for Q2 2025 and $87.4 million for Q1 2025.